Participated · Series C · Feb 2022

HARMAY operates a hybrid online-offline beauty retail platform renowned for its uniquely designed, street-facing concept stores and data-driven merchandising strategy. Since opening its first physical location in 2017, the company has expanded to nine stores across China and maintains an award-winning in-house architectural design team. Its assortment now exceeds 9,000 SKUs sourced from over 400 international beauty and lifestyle brands, with more than 100 new labels added in 2021 alone. HARMAY leverages big data and a team of buyers to continuously identify emerging niche products and refresh its offering. The company plans to extend its brick-and-mortar footprint to Wuhan, Guangzhou, and Shenzhen while launching a dedicated mobile app to complement its existing WeChat mini-program. Beyond retailing third-party brands, the firm is expanding its own portfolio, having recently acquired Kevyn Aucoin Beauty and deepened collaborations with L’Oréal Group brands. Today the business employs over 400 people and positions itself as an innovator in omnichannel beauty and lifestyle shopping experiences.

Led · Series A · Mar 2020

Eccang Technology, founded in Shenzhen in 2013, builds cross-border e-commerce software and middleware and operates a full mid-platform system. Its product suite expanded from four core offerings to 12 product lines, including cross-border seller ERP, overseas warehouse WMS, freight-forwarding TMS, M2B, BI, SRM, DWMS, cloud WMS and DMS. The company serves thousands of customers, naming Deppon Logistics, Ward Industrial, Barn, Global Starlight and Capesi among clients. It employs more than 260 people, with roughly 50% in the technical team. Eccang plans to use the nearly $10M Series A to fund software R&D, recruit high-end cross-border talent, drive customer growth and build its ecosystem. Management says it will continue investing in product innovation, stability and upgrades to deliver more efficient, lower-cost intelligent collaboration for cross-border sellers.

Led · Series A · May 2017

LGD-Gaming is a comprehensive professional esports club that fields teams in League of Legends, DOTA2, Honor of Kings, Overwatch, CS:GO and runs a women’s team. The club emphasizes a long‑standing youth training system and talent scouting powered by data to develop players. It generates revenue from commercial sponsorships, self-run events, player commercial activities, prize money and e‑commerce merchandise, with sponsorships as the primary source. Annual revenue is reported at RMB 40–50 million and the club expects to reach break‑even within two years. With the new funding LGD plans to increase investment in its academy and has already signed and renewed contracts with promising academy and star players. The club is also beginning to enter commercial real estate to build an “esports town” aligned with LPL’s move to an alliance and home‑and‑away system.

Participated · Series C · Aug 2015

Avitide discovers, manufactures and supplies molecule-specific biopharmaceutical affinity purification solutions. Its proprietary affinity separation technology is designed to accelerate bioprocess development timelines, reduce program risk, enable predictable commercial scalability, and lower manufacturing costs for batch and continuous operations. Avitide’s high-resolution affinity resins can be tailored to enrich for improved drug safety, potency, and quality attributes and the company delivers exclusive biomanufacturing intellectual property. The platform has been deployed against enzymes, antibody-based therapeutics, recombinant vaccines, and gene therapies and the company offers an industry-leading 3-month service timeline. The Series E proceeds will be used to fund ongoing operations with a target to reach profitability by 2019. Avitide’s management team brings substantial expertise and the company is financed by several venture firms including Polaris, OrbiMed, Mithril, SV Life Sciences, NeoMed, and Borealis. Avitide is described in the article as a company developing protein therapeutics. The piece links the company to Tillman Gerngross and names Kevin Isett as CEO. The headline and text indicate Avitide returned to the venture market to raise additional capital. A year earlier Isett told the publication that a $7.6 million round would be plenty to take the company to unspecified milestones. The article does not provide operating metrics, product program details, or explicit plans for the new funds. No valuation or financial terms beyond the reported raise are disclosed in the article. Avitide develops an affinity purification and protein-engineering platform designed to produce highly pure, hard-to-replicate biologics and to aid biosimilar development. Its technology separates impurities previously thought impossible to remove and can shrink typical purification processes from five or six steps to one or two, reducing product loss. The platform both enables creation of complex molecules and supports reverse-engineering of existing biologics for biosimilar makers. Avitide was spun out from Dartmouth College in 2013 and is chaired by Tillman Gerngross. The company licenses the technology to biopharma clients and is using recent funding to scale its manufacturing and commercial partnerships. Management says the raise is relatively small for biotech but expects to reach profitability three to four years after launch. Avitide develops customized affinity purification products and a platform to discover affinity purification resins for monoclonal antibodies, therapeutic proteins, and recombinant vaccines. Its technology enables rapid development of highly selective chromatography resins via chemical synthesis rather than costly recombinant proteins. The platform is designed to reduce bioprocess development timelines, program risk, and manufacturing costs by providing turnkey, high-capacity, low-cost affinity resins and single-step purification solutions. Proceeds from the Series A will support further development of the custom affinity purification platform and continued commercial development of affinity resins. The company is led by founders with extensive bioprocessing experience, including Tillman Gerngross, Errik Anderson, Kevin Isett, Warren Kett, and Jonathan Sheller. Avitide will initiate operations in Lebanon, New Hampshire, leveraging the local entrepreneurial and scientific talent near Dartmouth College.